MX371073B - Método para utilizar ciclodextrina. - Google Patents
Método para utilizar ciclodextrina.Info
- Publication number
- MX371073B MX371073B MX2014012200A MX2014012200A MX371073B MX 371073 B MX371073 B MX 371073B MX 2014012200 A MX2014012200 A MX 2014012200A MX 2014012200 A MX2014012200 A MX 2014012200A MX 371073 B MX371073 B MX 371073B
- Authority
- MX
- Mexico
- Prior art keywords
- cellular
- cyclodextrin
- diabetes
- cholesterol
- relating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen métodos para utilizar ciclodextrina para tratar, inhibir, prevenir, aliviar o curar la diabetes o afecciones relacionadas con la diabetes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261624087P | 2012-04-13 | 2012-04-13 | |
PCT/US2013/036484 WO2013155485A2 (en) | 2012-04-13 | 2013-04-12 | Method of using cyclodextrin |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014012200A MX2014012200A (es) | 2015-06-17 |
MX371073B true MX371073B (es) | 2020-01-15 |
Family
ID=49328287
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014012200A MX371073B (es) | 2012-04-13 | 2013-04-12 | Método para utilizar ciclodextrina. |
MX2020000205A MX2020000205A (es) | 2012-04-13 | 2013-04-12 | Metodo para utilizar ciclodextrina. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020000205A MX2020000205A (es) | 2012-04-13 | 2013-04-12 | Metodo para utilizar ciclodextrina. |
Country Status (8)
Country | Link |
---|---|
US (4) | US10195227B2 (es) |
EP (2) | EP4299121A3 (es) |
JP (4) | JP6491089B2 (es) |
CN (2) | CN111419870A (es) |
CA (1) | CA2870316C (es) |
ES (1) | ES2959119T3 (es) |
MX (2) | MX371073B (es) |
WO (1) | WO2013155485A2 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4299121A3 (en) * | 2012-04-13 | 2024-07-24 | L&F Research LLC | Method of using cyclodextrin |
DK2968083T3 (da) | 2013-03-12 | 2021-12-13 | Primal Therapies Inc | Dental sammensætning, som omfatter chelator og base |
JP6418911B2 (ja) * | 2014-11-18 | 2018-11-07 | 学校法人中部大学 | Glp−1分泌促進剤 |
US20160361345A1 (en) | 2015-06-10 | 2016-12-15 | Vtesse, Inc. | Hydroxypropyl Beta-Cyclodextrin Compositions and Methods |
CN105395549A (zh) * | 2015-11-03 | 2016-03-16 | 天津医科大学总医院 | 烟酸的新用途 |
AU2017329084A1 (en) * | 2016-09-19 | 2019-05-09 | Aten Porus Lifesciences | Cyclodextrin based polymers, methods, compositions and applications thereof |
WO2018075622A1 (en) * | 2016-10-19 | 2018-04-26 | University Of Miami | Materials and methods for modulating insulin signaling and preserving podocyte function |
CN107982546A (zh) * | 2017-12-05 | 2018-05-04 | 中国药科大学 | 基于主客体相互作用的酸敏感超分子纳米粒及其应用 |
CA3114021A1 (en) | 2018-10-29 | 2021-05-07 | Cyclo Therapeutics, Inc. | Methods for treating alzheimer's disease |
US11279774B2 (en) | 2019-01-03 | 2022-03-22 | Underdog Pharmaceuticals, Inc. | Cyclodextrin dimers, compositions thereof, and uses thereof |
WO2020213010A1 (en) * | 2019-04-16 | 2020-10-22 | Celagenex Research (India) Pvt. Ltd. | Synergistic lipid controlling compositions |
US20230330133A1 (en) * | 2020-08-27 | 2023-10-19 | Beren Therapeutics P.B.C. | Methods for the treatment of cholesterol crystal embolization with cyclodextrins |
EP4203973A1 (en) * | 2020-08-27 | 2023-07-05 | Beren Therapeutics P.B.C. | Methods for the prevention of cholesterol crystal embolization with cyclodextrins |
US20240000826A1 (en) * | 2020-08-27 | 2024-01-04 | Beren Therapeutics P.B.C. | Methods for the treatment of cardiovascular disease with cyclodextrins |
CN112089843B (zh) * | 2020-10-13 | 2022-11-04 | 合肥工业大学 | 一种抗心力衰竭的联用组合药物及其在制备抗心力衰竭药物中的应用 |
CN113295793B (zh) * | 2021-05-20 | 2022-11-04 | 复旦大学附属中山医院 | 预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用 |
US20240238327A1 (en) * | 2021-09-01 | 2024-07-18 | Renatus Inc. | Pharmaceutical composition comprising gamma-cyclodextrin polymer and uses thereof |
WO2023156966A1 (en) | 2022-02-18 | 2023-08-24 | Beren Therapeutics P.B.C. | Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0672100B2 (ja) * | 1989-11-15 | 1994-09-14 | 株式会社上野製薬応用研究所 | 利尿剤 |
US5840713A (en) * | 1995-04-03 | 1998-11-24 | Weisz; Paul B. | Therapy for tissue membrane insufficiency |
CA2348292A1 (en) * | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Betacellulin protein-containing preparation |
US6756504B2 (en) | 2000-04-19 | 2004-06-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Sphingolipids |
US20040121983A1 (en) * | 2002-08-12 | 2004-06-24 | Council Of Scientific And Industrial Research | Method for treating leishmaniasis using methyl-beta-cyclodextrin |
DK1478401T3 (da) * | 2002-08-19 | 2010-01-18 | Artjen Complexus Inc | Sammensætninger omfattende næringsfedt-komplekser og fremgangsmåder til deres avnendelse |
JP2004323443A (ja) * | 2003-04-25 | 2004-11-18 | Tokai Univ | 抗血栓薬 |
WO2005000217A2 (en) * | 2003-06-06 | 2005-01-06 | Merck & Co., Inc. | Combination therapy for the treatment of dyslipidemia |
US9200245B2 (en) | 2003-06-26 | 2015-12-01 | Seng Enterprises Ltd. | Multiwell plate |
US7393826B2 (en) * | 2003-07-03 | 2008-07-01 | Lipid Sciences, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
US7276351B2 (en) | 2003-09-10 | 2007-10-02 | Seahorse Bioscience | Method and device for measuring multiple physiological properties of cells |
US20050129677A1 (en) * | 2003-12-10 | 2005-06-16 | Shengwen Li | Lipid rafts and clostridial toxins |
CN1282425C (zh) * | 2004-06-22 | 2006-11-01 | 王美岭 | 苹果醋营养品及其生产方法 |
US20060128653A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
JP2006191830A (ja) * | 2005-01-12 | 2006-07-27 | Unitika Ltd | 脂肪の蓄積を抑制する食品 |
ES2536177T3 (es) | 2005-01-27 | 2015-05-21 | Erimos Pharmaceuticals Llc | Formulaciones para la inyección de butanos catecólicos, incluyendo compuestos de NDGA, en animales |
US7670817B2 (en) | 2005-11-08 | 2010-03-02 | The General Hospital Corporation | Dynamin mediated diseases and associated methods and products |
US20090324624A1 (en) * | 2006-06-16 | 2009-12-31 | Florida Atlantic University | Chitin micro-particles as an adjuvant |
EP1894924A1 (en) * | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
EP2063879A2 (en) | 2006-10-20 | 2009-06-03 | ICOS Corporation | Compositions of chk1 inhibitors and cyclodextrin |
EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
WO2010042202A1 (en) | 2008-10-07 | 2010-04-15 | Fibrogen, Inc. | Methods for treatment of podocyte injury |
CN102438614A (zh) * | 2008-10-10 | 2012-05-02 | 利默里克生物制药公司 | 用于治疗的吡喃酮类似物 |
US8202702B2 (en) | 2008-10-14 | 2012-06-19 | Seahorse Bioscience | Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision |
US8263413B1 (en) | 2008-10-17 | 2012-09-11 | Andrew S Hansen | Methods for analyzing lipids and membrane proteins in biological matter using stable isotopes and mass spectrometry |
EP2352502A4 (en) | 2008-11-06 | 2012-12-26 | Univ Miami | LIMITED PROTEOLYSIS OF CD2AP AND PROGRESSION OF NURSE DISEASE |
WO2010103823A1 (ja) | 2009-03-12 | 2010-09-16 | パナソニック株式会社 | 画像表示装置および画像表示方法 |
US8975241B2 (en) * | 2009-10-08 | 2015-03-10 | Song Ho Biomed Co., Ltd. | Composition for treating and preventing obesity including high water-soluble 2-hydroxypropyl-betacyclodextrin as effective component |
US20120251527A1 (en) | 2009-11-06 | 2012-10-04 | University Of Miami | Podocyte specific assays and uses thereof |
US8372877B2 (en) * | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
WO2012012473A1 (en) | 2010-07-19 | 2012-01-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of delta tocopherol for the treatment of lysosomal storage disorders |
WO2012054321A2 (en) * | 2010-10-19 | 2012-04-26 | University Of Miami | Assays, methods and kits for predicting renal disease and personalized treatment strategies |
EP4299121A3 (en) * | 2012-04-13 | 2024-07-24 | L&F Research LLC | Method of using cyclodextrin |
-
2013
- 2013-04-12 EP EP23183457.3A patent/EP4299121A3/en active Pending
- 2013-04-12 JP JP2015505963A patent/JP6491089B2/ja active Active
- 2013-04-12 CA CA2870316A patent/CA2870316C/en active Active
- 2013-04-12 EP EP13775223.4A patent/EP2836221B1/en active Active
- 2013-04-12 MX MX2014012200A patent/MX371073B/es active IP Right Grant
- 2013-04-12 CN CN202010200900.6A patent/CN111419870A/zh active Pending
- 2013-04-12 CN CN201380019867.5A patent/CN104244956B/zh active Active
- 2013-04-12 WO PCT/US2013/036484 patent/WO2013155485A2/en active Application Filing
- 2013-04-12 MX MX2020000205A patent/MX2020000205A/es unknown
- 2013-04-12 ES ES13775223T patent/ES2959119T3/es active Active
- 2013-04-12 US US14/391,236 patent/US10195227B2/en active Active
-
2018
- 2018-08-10 JP JP2018150978A patent/JP2018203747A/ja active Pending
- 2018-12-20 US US16/227,018 patent/US10980828B2/en active Active
-
2021
- 2021-01-22 US US17/155,545 patent/US20210228616A1/en not_active Abandoned
- 2021-06-23 JP JP2021103893A patent/JP2021155436A/ja active Pending
-
2022
- 2022-09-21 US US17/949,672 patent/US20230338412A1/en active Pending
-
2023
- 2023-09-11 JP JP2023146755A patent/JP2023178518A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2959119T3 (es) | 2024-02-20 |
US10195227B2 (en) | 2019-02-05 |
JP2021155436A (ja) | 2021-10-07 |
JP6491089B2 (ja) | 2019-03-27 |
WO2013155485A2 (en) | 2013-10-17 |
WO2013155485A3 (en) | 2013-12-19 |
JP2015512949A (ja) | 2015-04-30 |
CN104244956B (zh) | 2020-04-17 |
MX2020000205A (es) | 2022-06-06 |
JP2018203747A (ja) | 2018-12-27 |
MX2014012200A (es) | 2015-06-17 |
EP2836221B1 (en) | 2023-07-05 |
JP2023178518A (ja) | 2023-12-15 |
US10980828B2 (en) | 2021-04-20 |
CN104244956A (zh) | 2014-12-24 |
EP2836221A2 (en) | 2015-02-18 |
EP4299121A3 (en) | 2024-07-24 |
US20210228616A1 (en) | 2021-07-29 |
US20150065457A1 (en) | 2015-03-05 |
EP4299121A2 (en) | 2024-01-03 |
US20230338412A1 (en) | 2023-10-26 |
EP2836221A4 (en) | 2016-07-27 |
CA2870316A1 (en) | 2013-10-17 |
US20190262385A1 (en) | 2019-08-29 |
CA2870316C (en) | 2022-04-19 |
CN111419870A (zh) | 2020-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX371073B (es) | Método para utilizar ciclodextrina. | |
MX346428B (es) | Metodo para tratar eccema. | |
HRP20181779T1 (hr) | Spojevi i postupci za modulaciju kinaze, te indikacije za njih | |
WO2013003601A9 (en) | Method for treating phytophotodermatitis | |
EP2892534B8 (en) | Compounds and methods for kinase modulation, and indications therefor | |
EP2542584B8 (en) | Methods for treating pancreatic cancer | |
DK2916860T3 (da) | En sammensætning til behandling af diabetes, som omfatter oxyntomodulinanalog | |
WO2014031792A3 (en) | Methods of treating epilepsy or status epilepticus | |
MX353579B (es) | Organoide hepatico, sus usos y metodo de cultivo para obtenerlos. | |
BR112012026112A2 (pt) | método de tratar obesidade usando moduladores de inflamação antioxidantes | |
AU2013200283A1 (en) | Wear assembly for machinery | |
UY34280A (es) | Nuevos compuestos que tienen actividad inhibidora frente a la daminoacido oxidasa. | |
WO2012177925A8 (en) | Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene | |
MX346395B (es) | Moduladores de actividad hec1 y sus metodos. | |
WO2013138568A8 (en) | Liver x receptor modulators | |
BR112015013152A2 (pt) | composição para tratamento de uma formação subterrânea , método para tratar uma formação subterrânea , e método para reduzir a viscosidade de óleo cru. | |
WO2011083483A3 (en) | Method for treatment of inflammatory disease and disorder | |
MX2014006157A (es) | Moduladores mejoradores de la actividad de hec1 y metodos para los mismos. | |
WO2012170720A3 (en) | Methods and compositions for treating brain cancer | |
EP2843045A4 (en) | METHOD FOR STABILIZING CHOLESTEROL OXIDASE | |
WO2013025939A9 (en) | Compounds and methods for treating cancer by inhibiting the urokinase receptor | |
EP2560648A4 (en) | METHOD OF TREATING PANCREATIC CANCER | |
WO2013021208A3 (en) | Multi-photon isomerisation of combretastatins and their use in therapy | |
WO2013013238A3 (en) | Compounds and related compositions and methods of use | |
FI20106068A0 (fi) | Anioninen dispersiopolymerointimenetelmä |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: L&F RESEARCH LLC |
|
FG | Grant or registration |